Full Press Release Details
Daix (France), New York (United States), February 26, 2026–Inventiva(Euronext Paris and NASDAQ:IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events:
TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date:Monday, March 2, 2026Time of fireside chat:10:30am ESTLocation:Boston, Massachusetts
Leerink Global Healthcare Conference – March 9-11, 2026Date:Tuesday, March 10, 2026Time of presentation:10:00am EDTLocation:Miami, Florida
Barclays 28th Annual Global Healthcare Conference – March 10-12, 2026Date:Wednesday, March 11, 2026Time of fireside chat:11:00am EDTLocation:Miami, Florida
UBS Biotech Conference: Catalyst for Change – March 8-10, 2026Location:Miami, Florida
The presentation and fireside chats will be webcast and can be accessed by visiting theInvestor Presentationssection of the website.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an oral small molecule therapy for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).https://www.inventivapharma.com
Contacts
| Investor RelationsDavid Nikodem:IR@inventivapharma.comPatricia L. Bank:patti.bank@icrhealthcare.com | Media RelationsPascaline Clerc:media@inventivapharma.comAlexis Feinberg:inventivapr@icrhealthcare.com |